Ju Fu Tang Biotech Holdings Co., Ltd. (GEM: 08217) reported a marked turnaround for the year ended 31 March 2026, moving from a HK$5.90 million loss in FY2025 to a HK$23.32 million profit attributable to shareholders, driven mainly by sizeable fair-value gains on listed equity investments.

Financial highlights 1. Revenue rose 3.7% year on year to HK$37.56 million (FY2025: HK$36.20 million), supported by the first-time contribution of HK$2.11 million from the newly launched health-technology and medical-device sales segment. Core civil engineering and renovation revenue eased 2.1% to HK$35.44 million. 2. Gross profit inched up 3.6% to HK$1.02 million; gross margin was stable at 2.7%. 3. Other gains surged to HK$30.19 million (FY2025: HK$5.35 million), mainly reflecting a HK$27.39 million uplift in the fair value of financial assets at fair value through profit or loss (FVTPL). 4. Administrative and other operating expenses fell 8.8% to HK$8.53 million, aided by lower staff costs. 5. Finance costs were unchanged at HK$0.72 million, tied to a HK$12.00 million bond payable. 6. Basic earnings per share reached 7.72 HK cents (FY2025: loss per share of 1.95 HK cents).

Balance-sheet developments • Cash and bank balances quadrupled to HK$9.28 million, while FVTPL assets climbed 83.1% to HK$51.38 million, underscoring the Group’s shift toward financial investments. • Net assets expanded to HK$50.54 million (FY2025: HK$27.22 million). • The current ratio improved to 2.2x from 1.5x, and the gearing ratio (interest-bearing debt/total equity) narrowed to 24% from 44%, reflecting strengthened liquidity and lower leverage. • Trade receivables (net) dropped 54.4% to HK$11.88 million after a HK$5.96 million impairment charge, offset by a HK$7.20 million reversal on contract assets.

Investment portfolio As at 31 March 2026, listed equity investments totalled HK$51.38 million, equivalent to 55.5% of total assets. Key holdings included: • Asia Strategy Digit Technology Holdings – HK$27.85 million (30.1% of total assets) • Tam Kam Holdings – HK$10.24 million (11.1%) • WLS Holdings – HK$3.82 million (4.1%)

Operational update The Group held 13 construction contracts in progress with an aggregate value of HK$394.23 million at period-end, up from 12 contracts worth HK$346.89 million a year earlier. Headcount stood at 23 (FY2025: 22). No dividends were declared for the year.

Outlook and strategy Management reiterated its investment policy focused on optimising idle funds through diversified listed-equity positions while maintaining sufficient liquidity for core civil-engineering operations and the new health-technology initiative. The Board reported no material post-balance-sheet events up to the announcement date.